Wall Street rallies on coronavirus vaccine trial results

By Sinéad Carew NEW YORK (Reuters) - The S&P 500 ended higher but closed just shy of a record on Monday as investors bet that a full economic reopening was finally in sight following the first positive data from a late-stage COVID-19 vaccine trial.

Reuters November 10, 2020 03:05:09 IST
Wall Street rallies on coronavirus vaccine trial results

coronavirus vaccine trial results" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/10/2020-11-09T122502Z_2_LYNXMPEGA80GL_RTROPTP_2_USA-ELECTION-POLLING.jpg" alt="Wall Street rallies on coronavirus vaccine trial results" width="300" height="225" />

By Sinéad Carew

NEW YORK (Reuters) - The S&P 500 ended higher but closed just shy of a record on Monday as investors bet that a full economic reopening was finally in sight following the first positive data from a late-stage COVID-19 vaccine trial.

Oil prices soared and pushed up energy stocks while safe-haven U.S. Treasuries sold off after U.S. drugmaker Pfizer and its German partner BioNTech said a large-scale trial of their vaccine showed it was more than 90% effective in preventing COVID-19 .

Saturday's news that Joe Biden had won the U.S. presidential election was also a reassuring confirmation of what investors had already been counting on by the end of last week, according to market strategists.

"Election uncertainty is fading into the rearview mirror. Now we have this boost of investor enthusiasm after the vaccine news," said to Michael Antonelli, market strategist at Baird in Milwaukee. "All the types of companies that would benefit from us returning to a pre-COVID world are the big winners today."

Sectors such as energy, travel and financials which were among the hardest hit by lockdowns aimed at curbing the virus were some of the biggest percentage gainers on Monday.

While the vaccine study is still ongoing and requires approval, Pfizer and BioNTech said they had found no serious safety concerns so far and expected to seek U.S. emergency use authorization later this month.

"It's not that we're out of the woods with COVID. It's that the vaccine starts to remove the worst case scenario that we surge out of control and go back into a national lockdown," said Antonelli. "The market's looking into the future, to the first and second quarter of next year."

Unofficially, the Dow Jones Industrial Average <.DJI> rose 839.61 points, or 2.96%, to 29,163.01, the S&P 500 <.SPX> gained 44.25 points, or 1.26%, to 3,553.69 and the Nasdaq Composite <.IXIC> dropped 162.91 points, or 1.37%, to 11,732.32.

The S&P energy index <.SPNY> led gainers among the S&P 500's 11 major sectors and registered its biggest daily percentage gain in months as investors bet demand would climb again when people become more comfortable with the idea of traveling as the health crisis subsides.

Also, bank shares <.SPXBK>, often seen as a proxy for the broader economy, soared.

The companies hit hardest by months of travel bans and lockdowns surged. The NYSE airlines index <.XAL> was up 19% while plane maker Boeing Co jumped 15%. Cruise line operator Carnival Corp was up more than 32%.

In contrast, the technology sector and specific companies that had outperformed during the pandemic as they were seen as "stay-at-home" winners were making smaller gains or declining.

Netflix Inc and Amazon.com Inc declined while Zoom Video and exercise bike maker Peloton Interactive Inc PTON.O> tumbled to limit the Nasdaq's advance.

"Stocks like tech are being served up as a form of proceeds to fund the purchase of pro-cyclical stocks that would stand to benefit from the economic reopening that could be accelerated by way of a vaccine," said Mark Luschini, chief investment strategist at Janney Montgomery Scott in Philadelphia.

Stocks around the world had already been gaining ground before the vaccine data pushed equities even higher as expectations of better global trade ties and more monetary stimulus under U.S. President-elect Biden was already lifting demand for risky assets.

Pfizer shares closed sharply higher after soaring as much as 15.4% during the session. But another drugmaker Biogen Inc slumped as a panel of experts to the U.S. health regulator voted against the drugmaker's experimental Alzheimer's treatment.

(Additional reporting by Medha Singh and Shivani Kumaresan in Bengaluru; Editing by Shounak Dasgupta, Arun Koyyur, Patrick Graham and Tom Brown)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

U.S. data suggest economic recovery may be weakening
Business

U.S. data suggest economic recovery may be weakening

By Howard Schneider WASHINGTON (Reuters) - The explosive surge in U.S. coronavirus cases this fall has left a question hanging: When will the economy take its own turn for the worse

Fed, ECB heads give COVID-19 vaccine cautious welcome
Business

Fed, ECB heads give COVID-19 vaccine cautious welcome

FRANKFURT/WASHINGTON (Reuters) - The heads of the Federal Reserve and the European Central Bank welcomed the encouraging results in trials of a vaccine candidate for the novel coronavirus but stressed that the economic outlook will remain uncertain. Fed chair Jay Powell and ECB President Christine Lagarde said the economy was still in for a tough time even if the development of a potential vaccine by U.S. drugmaker Pfizer and German partner BioNTech SE was reason for some optimism further ahead

India's October fuel demand marks first year-on-year gain in 8 months
Business

India's October fuel demand marks first year-on-year gain in 8 months

By Sumita Layek (Reuters) - India's fuel consumption in October registered its first year-on-year increase since February, as slowing coronavirus cases and increased mobility accelerated an economic recovery, data showed on Thursday.